Kennedy Capital Management
SAGE icon

Kennedy Capital Management’s Sage Therapeutics SAGE Stock Holding History

Kennedy Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-29,102
Closed -$4.11M – 728
2018
Q3 		$4.11M Buy
29,102
+809
+3% +$125K 0.08% 459
2018
Q2 		$4.43M Buy
28,293
+1,293
+5% +$203K 0.08% 450
2018
Q1 		$4.35M Buy
+27,000
New +$4.58M 0.08% 444

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
OppenheimerFunds
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Kennedy Capital Management's SAGE Position: Q4 2018 in Review

Kennedy Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 29,102 shares — an estimated $4.11M sold.

Kennedy Capital Management first reported a position in SAGE in Q1 2018 and held it in 3 quarters. The position peaked at $4.43M in Q2 2018. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

  • Kennedy Capital Management reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kennedy Capital Management sold 29,102 Sage Therapeutics shares in Q4 2018, an estimated $4.11M.
  • Kennedy Capital Management first reported a position in Sage Therapeutics in Q1 2018 and held it in 3 quarters.
  • Kennedy Capital Management's Sage Therapeutics position peaked at $4.43M in Q2 2018.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Kennedy Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.